Calgary-based virtual pharmacy PurposeMed is completing its U.S. expansion this month, bringing its popular Freddie service ...
MedPage Today on MSN
CDC Backs Twice-Yearly Injectable for HIV Prevention
The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...
A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6 monthly HIV PrEP ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On ...
By ensuring timely wound care, vaccination, immunoglobulin administration, and responsible interaction with animals, rabies ...
A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
LoveBScott on MSN
MISTR & SISTR Launch First-Ever National PrEP Day: A Bold Move to End HIV in the U.S.
Oct. 10, 2025, is officially the first-ever National PrEP Day, and MISTR and SISTR are going big. Their goal? Get 10,000 new ...
Patrick Sullivan, DVM, PhD, an infectious disease epidemiologist and professor of epidemiology at Emory University in Atlanta, Georgia, spoke about his recent analysis that revealed that modest ...
A new survey launched by Global Black Gay Men Connect is seeking responses from Black gay men and Black trans community ...
The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which is viewed as a key part of the drugmaker's growth strategy in HIV. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback